ADIPOQ and diabetes mellitus: In additional subgroup analyses, trial results remained virtually unchanged after excluding 17 participants that used diabetes medications at baseline (data not shown) and there were no statistically significant differences across study centers, or by category of body mass index, baseline plasma Se concentrations, or baseline adiponectin concentrations (data not shown).